http://jnci.oxfordjournals.org/content/100/1/14.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/100/1/14" />
      <meta content="/jnci/100/1/14.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials"
            name="DC.Title" />
      <meta content="10.1093/jnci/djm252" name="DC.Identifier" />
      <meta content="2008-01-02" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Alessandra Gennari" name="DC.Contributor" />
      <meta content="Maria Pia Sormani" name="DC.Contributor" />
      <meta content="Paolo Pronzato" name="DC.Contributor" />
      <meta content="Matteo Puntoni" name="DC.Contributor" />
      <meta content="Mariantonietta Colozza" name="DC.Contributor" />
      <meta content="Ulrich Pfeffer" name="DC.Contributor" />
      <meta content="Paolo Bruzzi" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Alessandra Gennari" />
      <meta name="citation_author" content="Maria Pia Sormani" />
      <meta name="citation_author" content="Paolo Pronzato" />
      <meta name="citation_author" content="Matteo Puntoni" />
      <meta name="citation_author" content="Mariantonietta Colozza" />
      <meta name="citation_author" content="Ulrich Pfeffer" />
      <meta name="citation_author" content="Paolo Bruzzi" />
      <meta content="HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials"
            name="citation_title" />
      <meta content="100" name="citation_volume" />
      <meta content="1" name="citation_issue" />
      <meta content="14" name="citation_firstpage" />
      <meta content="20" name="citation_lastpage" />
      <meta content="100/1/14" name="citation_id" />
      <meta content="100/1/14" name="citation_id_from_sass_path" />
      <meta content="jnci;100/1/14" name="citation_mjid" />
      <meta content="10.1093/jnci/djm252" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/100/1/14.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/100/1/14.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/100/1/14.full.pdf"
            name="citation_pdf_url" />
      <meta content="/content/100/1.cover.gif" name="issue_cover_image" />
      <meta content="http://jnci.oxfordjournals.org/content/100/1/14"
            name="citation_public_url" />
      <meta content="18159072" name="citation_pmid" />
      <meta name="citation_section" content="Article" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/100/1/13.short" rel="prev" />
      <link href="/content/100/1/21.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d392425737e1">var callbackToken='53789CC5305E436';</script><script type="text/javascript" id="session-d392425737e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:15:25.667-07:00';
            var gSessionId = 'mvIC@CJL4eKh3UP@32hq@A';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djm252");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20080102");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F100%2F1%2F14.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/100/1.toc">
                  <span xmlns="" class="volume-value">Volume 100</span>
                  <span xmlns="" class="issue-value"> Issue 1</span></a></li>
            <li>Pp. <span class="slug-pages">
                  14-20.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/100/1/14.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline"><em>HER2</em> Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials
               </h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Alessandra+Gennari&amp;sortspec=date&amp;submit=Submit">Alessandra Gennari</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Maria+Pia+Sormani&amp;sortspec=date&amp;submit=Submit">Maria Pia Sormani</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Paolo+Pronzato&amp;sortspec=date&amp;submit=Submit">Paolo Pronzato</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Matteo+Puntoni&amp;sortspec=date&amp;submit=Submit">Matteo Puntoni</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Mariantonietta+Colozza&amp;sortspec=date&amp;submit=Submit">Mariantonietta Colozza</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Ulrich+Pfeffer&amp;sortspec=date&amp;submit=Submit">Ulrich Pfeffer</a></span> and 
                     </li>
                     <li class="last" id="contrib-7"><span class="name"><a class="name-search"
                              href="/search?author1=Paolo+Bruzzi&amp;sortspec=date&amp;submit=Submit">Paolo Bruzzi</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><strong>Affiliations of authors:</strong> National Cancer Research Institute, Genoa, Italy (AG, PP, UP, PB); Department of Health Sciences, University of Genoa, Genoa,
                           Italy (AG, MPS, MP); Galliera Hospital, Genoa, Italy (MP); Perugia Hospital, Perugia, Italy (MC)
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><strong>Correspondence to:</strong><br /> Alessandra Gennari, MD, PhD, National Cancer Research Institute, Largo Rosanna Benzi, 10 16132 Genoa, Italy (e-mail: <span class="em-link"><span class="em-addr">alessandra.gennari{at}istge.it</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2007-04-04"><span class="received-label">Received </span>April 4, 2007.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2007-10-23"><span class="rev-recd-label">Revision received </span>October 23, 2007.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2007-11-09"><span class="accepted-label">Accepted </span>November 9, 2007.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-11" title="Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  <div id="sec-1" class="subsection">
                     <p id="p-1"><strong>Background</strong> Adjuvant chemotherapy with anthracyclines improves disease-free and overall survival compared with non–anthracycline-based
                        adjuvant chemotherapy regimens in the treatment of early breast cancer. The role of <em>HER2</em> status as a marker of anthracycline responsiveness has been explored by subset analyses within randomized clinical trials,
                        with inconsistent results. We performed a pooled analysis of the interaction between <em>HER2</em> status and the efficacy of adjuvant anthracyclines based on the published subset data.
                     </p>
                  </div>
                  <div id="sec-2" class="subsection">
                     <p id="p-2"><strong>Methods</strong> We searched literature databases to identify randomized trials that compared anthracycline-based with non–anthracycline-based
                        adjuvant chemotherapy regimens in the treatment of early breast cancer and reported efficacy data according to <em>HER2</em> status. Log hazard ratios (HRs) for disease-free and overall survival were pooled across the studies according to <em>HER2</em> status by inverse variance weighting. A pooled test for treatment by <em>HER2</em> status interaction was performed by weighted linear meta-regression. All statistical tests were two-sided.
                     </p>
                  </div>
                  <div id="sec-3" class="subsection">
                     <p id="p-3"><strong>Results</strong> Eight studies (with 6564 randomly assigned patients, of whom 5354 had <em>HER2</em> status information available) were eligible for this analysis. In <em>HER2</em>-positive disease (n = 1536 patients), anthracyclines were superior to non–anthracycline-based regimens in terms of disease-free
                        (pooled HR of relapse = 0.71; 95% confidence interval [CI] = 0.61 to 0.83; <em>P</em> &lt; .001) and overall (pooled HR of death from any cause = 0.73; 95% CI = 0.62 to 0.85; <em>P</em> &lt; .001) survival. In <em>HER2</em>-negative disease (n = 3818 patients), anthracyclines did not improve disease-free (HR = 1.00; 95% CI = 0.90 to 1.11; <em>P</em> = .75) or overall (HR = 1.03; 95% CI = 0.92 to 1.16; <em>P</em> = .60) survival. The test for treatment by <em>HER2</em> status interaction yielded statistically significant results: for disease-free survival, the chi-square statistic for interaction
                        was 13.7 (<em>P</em> &lt; .001), and for overall survival, it was 12.6 (<em>P</em> &lt; .001).
                     </p>
                  </div>
                  <div id="sec-4" class="subsection">
                     <p id="p-4"><strong>Conclusions</strong> The added benefits of adjuvant chemotherapy with anthracyclines appear to be confined to women who have <em>HER2</em> overexpressed or amplified breast tumors.
                     </p>
                  </div>
               </div>
               <p id="p-5">
                  <div class="boxed-text" id="boxed-text-1">
                     <div id="sec-5" class="subsection">
                        <h4>CONTEXT AND CAVEATS</h4>
                        <div id="sec-6" class="subsection">
                           <h5>Prior knowledge</h5>
                           <p id="p-6">In the treatment of early breast cancer, anthracycline-based adjuvant chemotherapy improves disease-free and overall survival
                              compared with non–anthracycline-based adjuvant chemotherapy. However, it is unclear whether the <em>HER2</em> status of breast tumors is a marker of anthracycline responsiveness.
                           </p>
                        </div>
                        <div id="sec-7" class="subsection">
                           <h5>Study design</h5>
                           <p id="p-7">A pooled analysis of data from eight randomized controlled trials that compared anthracycline-based with non–anthracycline-based
                              adjuvant chemotherapy regimens in the treatment of early breast cancer.
                           </p>
                        </div>
                        <div id="sec-8" class="subsection">
                           <h5>Contribution</h5>
                           <p id="p-8">The added benefits of adjuvant chemotherapy with anthracyclines appear to be limited to women whose breast tumors have overexpressed
                              or amplified <em>HER2</em>.
                           </p>
                        </div>
                        <div id="sec-9" class="subsection">
                           <h5>Implications</h5>
                           <p id="p-9">Patients with <em>HER2</em>-negative breast tumors derive no added benefits from adjuvant chemotherapy with anthracyclines.
                           </p>
                        </div>
                        <div id="sec-10" class="subsection">
                           <h5>Limitations</h5>
                           <p id="p-10">Only eight randomized clinical trials published data on the effects of adjuvant anthracyclines according to <em>HER2</em> status. Summary results rather than individual patient data were analyzed, and there was no centralized reassessment of <em>HER2</em> status. The methods used to determine <em>HER2</em> status differed among the trials.
                           </p>
                        </div>
                     </div>
                  </div>
               </p>
               <p id="p-11">The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of randomized trials of polychemotherapy in early-stage
                  breast cancer demonstrated that anthracycline-based regimens are superior to non–anthracycline-based regimens with respect
                  to disease-free and overall survival (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>). However, the magnitude of the absolute benefit from adjuvant anthracyclines, although statistically significant, was modest
                  and not consistent across individual trials (<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>–<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>). An additional concern about the widespread use of anthracyclines as adjuvant treatment for early-stage breast cancer is
                  related to the small but clinically significant risks of cardiotoxicity and secondary leukemia that are associated with these
                  agents. Exploratory studies (<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>–<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>) have suggested that the benefit of adjuvant treatment with anthracyclines is confined mainly to women whose breast tumors
                  have overexpressed and/or amplified <em>HER2</em>. The association between <em>HER2</em> status and responsiveness to adjuvant anthracyclines may be related to the tumor level of topoisomerase II alpha, the molecular
                  target of anthracyclines. In fact, the gene encoding topoisomerase II alpha is located adjacent to the <em>HER2</em> oncogene on chromosome 17, and both genes are frequently coamplified in breast tumors (<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>). In this regard, some retrospective studies (<a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>) that have investigated the predictive value of aberrations in the topoisomerase II alpha gene in patients treated with anthracyclines
                  have suggested that the additional benefit of adjuvant anthracyclines might be limited to women whose breast tumors have amplification
                  of both the <em>HER2</em> and topoisomerase II alpha genes.
               </p>
               <p id="p-12">Data from several randomized clinical trials that compared anthracycline-based adjuvant chemotherapy with non–anthracycline-based
                  regimens have been subjected to subgroup analysis to examine whether the <em>HER2</em> status of a breast tumor is a predictive marker for response to adjuvant treatment with anthracyclines (<a id="xref-ref-8-3" class="xref-bibr" href="#ref-8">8</a>–<a id="xref-ref-15-2" class="xref-bibr" href="#ref-15">15</a>). Only two of these studies (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>,<a id="xref-ref-15-3" class="xref-bibr" href="#ref-15">15</a>) reported a positive association between <em>HER2</em> positivity and a better response to anthracycline-based regimens than to non–anthracycline-based regimens. Possible reasons
                  for this inconsistency include differences among the studies in the methods used to assess <em>HER2</em> status, incomplete specimen collection, and the administration, in some trials, of outdated or suboptimal adjuvant regimens.
                  Furthermore, subset analyses within individual studies that are intended to investigate the effects of an intervention for
                  specific subgroups of patients are inevitably plagued by chance effects and lack of power and should be regarded as exploratory
                  (<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>).
               </p>
               <p id="p-13">To better assess the differential efficacy of adjuvant anthracyclines according to <em>HER2</em> status, we performed a meta-analysis of data from published subset analyses that were conducted in the context of randomized
                  clinical trials that compared anthracycline-based adjuvant regimens with non–anthracycline-based adjuvant regimens in women
                  with early-stage breast cancer. The aim of this meta-analysis was to assess the presence and degree of interaction between
                  <em>HER2</em> status and use of adjuvant anthracyclines in the treatment of early breast cancer.
               </p>
               <div class="section" id="sec-11">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-15" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Methods</h2>
                  <div id="sec-12" class="subsection">
                     <h3>Identification and Selection of Trials</h3>
                     <p id="p-14">For this meta-analysis, we sought data from all English-language published (as full papers or as conference abstracts) and
                        unpublished randomized trials that compared anthracycline-based adjuvant chemotherapy with non–anthracycline-based adjuvant
                        chemotherapy in the treatment of early breast cancer and reported efficacy data according to <em>HER2</em> status. All trials had to fulfill the following criteria to be included in this meta-analysis: 1) the patients had to have
                        been randomly assigned; 2) the trial had to be designed to compare anthracycline-based with non–anthracycline-based chemotherapeutic
                        regimens in the adjuvant treatment of early breast cancer; and 3) hazard ratios for disease-free and overall survival according
                        to <em>HER2</em> status either had to be reported or could be computed from the data presented. Studies in which hazard ratios for disease-free
                        and/or overall survival according to <em>HER2</em> status were not reported or could not be computed from the data presented were excluded.
                     </p>
                     <p id="p-15">We searched for relevant trials 1) by performing computer-aided literature searches of the MEDLINE and CANCERLIT databases;
                        2) by examining the reference lists of published trials, review articles, and editorials on <em>HER2</em> status and efficacy of adjuvant anthracyclines; 3) by searching meetings abstracts; and 4) by consulting the US National
                        Cancer Institute Physicians Data Query Clinical Protocol. For database searches, the following strategy was used: “Breast
                        Neoplasms” [MeSH] AND “Chemotherapy, Adjuvant” [MeSH] AND (“Anthracyclines” [MeSH] OR “Anthracyclines/therapeutic use” [MeSH])
                        AND (“Receptor, erbB-2” [MeSH] OR “Genes, erbB-2” [MeSH]). The databases were searched for papers published through November
                        30, 2006.
                     </p>
                  </div>
                  <div id="sec-13" class="subsection">
                     <h3>Data Abstraction</h3>
                     <p id="p-16">The following data were abstracted from each study: the number of randomly assigned patients, the number of patients whose
                        tumors were assessed for <em>HER2</em>, the description of treatment regimens, the year of publication or disclosure (for data presented as conference abstracts
                        only), the outcome measures, and the treatment effect estimates. Hazard ratios (HRs) for breast cancer recurrence and all-cause
                        mortality were extracted (along with 95% confidence intervals [CIs]) by using the non–anthracycline-based adjuvant chemotherapy
                        arm as the reference group. All data were checked for internal consistency; principal investigators of the studies were contacted
                        to retrieve missing information or to clarify inconsistencies.
                     </p>
                  </div>
                  <div id="sec-14" class="subsection">
                     <h3>Statistical Methods</h3>
                     <p id="p-17">The primary endpoints of this analysis were disease-free and overall survival. This meta-analysis was performed using a fixed-effects
                        model. All trials reported <em>HER2</em>-specific hazard ratios with 95% confidence intervals. In the Belgian study (<a id="xref-ref-8-4" class="xref-bibr" href="#ref-8">8</a>), which compared two dose levels of epirubicin plus cyclophosphamide with cyclophosphamide, methotrexate, and 5-fluorouracil
                        (CMF), the hazard ratios for the two epirubicin-containing arms vs CMF were pooled by inverse variance weighting. Log hazard
                        ratios for disease-free and overall survival were pooled across the studies, both overall and according to <em>HER2</em> status by inverse variance weighting. Formal tests for treatment by <em>HER2</em> status interaction were performed for each study, and the results of such tests were compared with those of interaction tests
                        reported by the individual studies. A pooled test for treatment by <em>HER2</em> status interaction was performed using a weighted linear meta-regression of the log hazard ratio with <em>HER2</em> status as a binary covariate (positive/negative). Publication bias was assessed by visual inspection of funnel plots for
                        study size against treatment effect (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>) and with Egger's regression asymmetry test (<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>). Sensitivity analyses were performed to examine whether the strength of interaction between <em>HER2</em> status and the efficacy of adjuvant anthracycline treatment was associated with the method of <em>HER2</em> assessment, the type of anthracycline-based regimen used, or the proportion of patients who were assessed for <em>HER2</em> status. All analyses were conducted with the use of Stata statistical software (version 9, Stata Corp., College Station,
                        TX). All <em>P</em> values were two-sided and the cutoff for statistical significance was .05.
                     </p>
                  </div>
               </div>
               <div class="section" id="sec-15">
                  <div class="section-nav"><a href="#sec-11" title="Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-19" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Results</h2>
                  <p id="p-18">We identified nine randomized trials (<a id="xref-ref-8-5" class="xref-bibr" href="#ref-8">8</a>–<a id="xref-ref-15-4" class="xref-bibr" href="#ref-15">15</a>,<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>) that compared anthracycline-based with non–anthracycline-based regimens and that analyzed outcomes according to <em>HER2</em> status; seven trials (<a id="xref-ref-8-6" class="xref-bibr" href="#ref-8">8</a>–<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>,<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>–<a id="xref-ref-15-5" class="xref-bibr" href="#ref-15">15</a>) were published as full articles in peer-reviewed journals, and two (<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>,<a id="xref-ref-20-2" class="xref-bibr" href="#ref-20">20</a>) were published as conference abstracts. One of the trials published as a conference abstract (<a id="xref-ref-20-3" class="xref-bibr" href="#ref-20">20</a>) was excluded because it reported <em>P</em> values but no other data that would allow us to estimate the hazard ratio according to <em>HER2</em> status. <a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a> presents the characteristics of the eight trials included in the meta-analysis.
                  </p>
                  <div class="table pos-float" id="T1">
                     <div class="table-inline">
                        <div class="callout"><span>View this table:</span><ul class="callout-links">
                              <li><a href="14/T1.expansion.html">In this window</a></li>
                              <li><a class="in-nw" href="14/T1.expansion.html">In a new window</a></li>
                           </ul>
                        </div>
                     </div>
                     <div class="table-caption"><span class="table-label">Table 1</span> 
                        <p id="p-19" class="first-child">Characteristics of the eight studies included in the pooled analysis of anthracycline-based adjuvant chemotherapy vs non–anthracycline-based
                           adjuvant chemotherapy for early breast cancer*
                        </p>
                        <div class="sb-div caption-clear"></div>
                     </div>
                  </div>
                  <div id="sec-16" class="subsection">
                     <h3><em>HER2</em> Status Assessment
                     </h3>
                     <p id="p-21">The proportion of randomly assigned patients who had the <em>HER2</em> status of their breast tumors assessed ranged from 46% to 94% (<a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a>). Overall, 5354 (82%) of the 6564 randomly assigned patients were assessed for <em>HER2</em> status. Among the patients whose <em>HER2</em> status was assessed, 1536 (29%) had tumors that overexpressed the HER2 protein or had amplification of the <em>HER2</em> gene. <em>HER2</em> status was evaluated by immunohistochemical assay alone in five studies (<a id="xref-ref-10-3" class="xref-bibr" href="#ref-10">10</a>–<a id="xref-ref-14-2" class="xref-bibr" href="#ref-14">14</a>); by fluorescence in situ hybridization alone or as a complement to immunohistochemical assay in two studies (<a id="xref-ref-8-8" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-9-3" class="xref-bibr" href="#ref-9">9</a>); and by immunohistochemical assay, fluorescence in situ hybridization, and the polymerase chain reaction in one study (<a id="xref-ref-15-7" class="xref-bibr" href="#ref-15">15</a>). Despite this heterogeneity, the prevalence of <em>HER2</em>-positive tumors was reasonably constant among the eight studies, ranging from 19% to 37%. Details about <em>HER2</em> testing and the scoring criteria from the individual studies are listed in <a id="xref-table-wrap-2-2" class="xref-table" href="#T2">Table 2</a>.
                     </p>
                     <div class="table pos-float" id="T2">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="14/T2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="14/T2.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 2</span> 
                           <p id="p-22" class="first-child">Assessment of <em>HER2</em> status in the eight studies included in the meta-analysis*
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-17" class="subsection">
                     <h3>Interaction Between <em>HER2</em> Status and Treatment Effect
                     </h3>
                     <p id="p-27">Data on disease-free survival were available for six studies (<a id="xref-ref-8-10" class="xref-bibr" href="#ref-8">8</a>–<a id="xref-ref-11-4" class="xref-bibr" href="#ref-11">11</a>,<a id="xref-ref-13-4" class="xref-bibr" href="#ref-13">13</a>,<a id="xref-ref-15-9" class="xref-bibr" href="#ref-15">15</a>) No disease-free survival data were available in the Gruppo Universitario Napoletano 3 study (<a id="xref-ref-12-4" class="xref-bibr" href="#ref-12">12</a>). Methodologic issues concerning an inconsistency between overall survival and disease-free survival data prevented inclusion
                        of disease-free survival data from the Gruppo Oncologico Italiano di Ricerca Clinica study (<a id="xref-ref-14-4" class="xref-bibr" href="#ref-14">14</a>) in the present analysis. Data on overall survival were reported in all studies except the Belgian study (<a id="xref-ref-8-11" class="xref-bibr" href="#ref-8">8</a>). Overall, compared with non–anthracycline-based adjuvant chemotherapy regimens, anthracycline-based adjuvant chemotherapy
                        was associated with a statistically significant reduction in the risk of relapse (pooled HR = 0.90; 95% CI = 0.82 to 0.98;
                        <em>P</em> = .01) and a borderline statistically significant reduction in the risk of death from any cause (pooled HR = 0.91; 95% CI
                        = 0.79 to 1.04; <em>P</em> = .056) (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Figs. 1</a> and <a id="xref-fig-2-1" class="xref-fig" href="#F2">2</a>). There was no statistically significant heterogeneity among the trials for either outcome variable.
                     </p>
                     <div id="F1" class="fig pos-float odd">
                        <div class="fig-inline"><a href="14/F1.expansion.html"><img alt="Fig. 1" src="14/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="14/F1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="14/F1.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/100/1/14/F1">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Fig. 1</span> 
                           <p id="p-28" class="first-child">Disease-free survival. Hazard ratios (HR, <strong>diamonds</strong>) and 95% confidence intervals (CIs, <strong>horizontal bars</strong>) of anthracycline-based vs non–anthracycline-based regimens in <em>HER2</em>-positive (<strong>black diamonds</strong>) and <em>HER2</em>-negative (<strong>gray diamonds</strong>) patients. Hazard ratios and their 95% confidence intervals (CIs) were abstracted from each study and combined to obtain
                              a pooled estimate (<strong>white diamond, dotted line</strong>) of the effect of anthracycline-based regimens. Chi-square (χ<sup>2</sup>) test statistics were used to test for the presence of heterogeneity across studies both in <em>HER2</em>-positive and in <em>HER2</em>-negative patients. A pooled test for treatment by <em>HER2</em> status interaction was performed using an inverse variance weighted linear meta-regression; the χ<sup>2</sup> statistic assessing the interaction was 13.7, <em>P</em> &lt; .001. NSABP = National Surgical Adjuvant Breast and Bowel Project; DBCG = Danish Breast Cancer Cooperative Group; NCIC
                              = National Cancer Institute of Canada.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F2" class="fig pos-float odd">
                        <div class="fig-inline"><a href="14/F2.expansion.html"><img alt="Fig. 2" src="14/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="14/F2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="14/F2.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/100/1/14/F2">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Fig. 2</span> 
                           <p id="p-29" class="first-child">Overall survival. Hazard ratios (HR, <strong>diamonds</strong>) and 95% confidence intervals (CIs, <strong>horizontal bars</strong>) of anthracycline-based vs non–anthracycline-based regimens in <em>HER2</em>-positive (<strong>black diamonds</strong>) and <em>HER2</em>-negative (<strong>gray diamonds</strong>) patients. Hazard ratios and their 95% confidence intervals were abstracted from each study and combined to obtain a pooled
                              estimate (<strong>white diamond, dotted line</strong>) of the effect of anthracycline-based regimens. Chi-square (χ<sup>2</sup>) test statistics were used to test for the presence of heterogeneity across studies both in <em>HER2</em>-positive and in <em>HER2</em>-negative patients. A pooled test for treatment by <em>HER2</em> status interaction was performed using an inverse variance weighted linear meta-regression; the χ<sup>2</sup> statistic assessing the interaction was 12.6, <em>P</em> &lt; .001. NSABP = National Surgical Adjuvant Breast and Bowel Project; GUN = Gruppo Universitario Napoletano; DBCG = Danish
                              Breast Cancer Cooperative Group; NCIC = National Cancer Institute of Canada.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-30">Among patients with <em>HER2</em>-positive breast tumors, anthracycline-based adjuvant chemotherapy was associated with a marked reduction in the risks of
                        relapse (pooled HR = 0.71, 95% CI = 0.61 to 0.83; <em>P</em> &lt; .001) and death (pooled HR = 0.73, 95% CI = 0.62 to 0.85; <em>P</em> &lt; .001). Conversely, among patients with <em>HER2</em>-negative breast tumors, there was no difference between those who received anthracycline-based adjuvant chemotherapy and
                        those who received non–anthracycline-based adjuvant chemotherapy with respect to disease-free (pooled HR of relapse = 1.00,
                        95% CI = 0.90 to 1.11; <em>P</em> = .75) or overall (pooled HR of death from any cause = 1.03, 95% CI = 0.92 to 1.16; <em>P</em> = .60) survival (<a id="xref-fig-1-2" class="xref-fig" href="#F1">Figs. 1</a> and <a id="xref-fig-2-2" class="xref-fig" href="#F2">2</a>). The test for treatment by <em>HER2</em> status interaction yielded statistically significant results: for disease-free survival, the chi-square statistic for interaction
                        was 13.7 (<em>P</em> &lt; .001), and for overall survival it was 12.6 (<em>P</em> &lt; .001), allowing us to reject the null hypothesis that the effect of adjuvant anthracyclines is independent of <em>HER2</em> status (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>).
                     </p>
                     <div class="table pos-float" id="T3">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="14/T3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="14/T3.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 3</span> 
                           <p id="p-31" class="first-child">Test for treatment by <em>HER2</em> status interaction*
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-33">Neither a visual assessment of funnel plots nor formal statistical tests (Egger's test for bias <em>P</em> &gt; .3; Begg's rank correlation test <em>P</em> &gt; .5) indicated the existence of publication bias, suggesting that studies in which anthracyclines showed a differential
                        effect on disease-free and/or overall survival according to <em>HER2</em> status were not more or less likely to be published than those that did not show such an effect.
                     </p>
                  </div>
                  <div id="sec-18" class="subsection">
                     <h3>Sensitivity Analyses</h3>
                     <p id="p-34">To examine whether the overall interaction observed between <em>HER2</em> status and the use of anthracyclines was due to an effect that was present only in some groups of trials, we conducted sensitivity
                        analyses in which patients were grouped according to the assessment method used to determine the <em>HER2</em> status of their tumors (immunohistochemistry vs fluorescence in situ hybridization), the type of anthracycline-based regimen
                        they received (doxorubicin vs epirubicin), and the proportion that was assessed for <em>HER2</em> status (&gt;60% vs ≤60%). The latter cutpoint was chosen because all but two studies had large proportions (ie, &gt;75%) of patients
                        assessed for <em>HER2</em> status. The magnitudes of the differential effects of anthracyclines in <em>HER2</em>-positive patients and in <em>HER2</em>-negative patients were remarkably similar across groups of trials (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Fig. 3</a>), suggesting that the interaction between anthracycline use and <em>HER2</em> status is independent of the type of <em>HER2</em> assay, the proportion of patients assessed for <em>HER2</em> status, and the type of anthracycline.
                     </p>
                     <div id="F3" class="fig pos-float odd">
                        <div class="fig-inline"><a href="14/F3.expansion.html"><img alt="Fig. 3" src="14/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="14/F3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="14/F3.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/100/1/14/F3">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Fig. 3</span> 
                           <p id="p-35" class="first-child">Sensitivity analyses. <strong>A</strong>) Disease-free survival. <strong>B</strong>) Overall survival. Pooled hazard ratios (HRs, <strong>diamonds</strong>) and 95% confidence intervals (CIs, <strong>horizontal bars</strong>) of anthracycline-based vs non–anthracycline-based regimens for <em>HER2</em>-positive (<strong>black diamonds</strong>) and <em>HER2</em>-negative (<strong>shaded diamonds</strong>) patients in each of the different subgroups examined. IHC = immunohistochemistry; FISH = fluorescent in situ hybridization.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
               </div>
               <div class="section" id="sec-19">
                  <div class="section-nav"><a href="#sec-15" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-20" title="Funding" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Discussion</h2>
                  <p id="p-36">We conducted this meta-analysis to examine whether anthracycline-based adjuvant chemotherapy would be more efficacious than
                     non–anthracycline-based adjuvant chemotherapy in <em>HER2</em>-positive women but not in <em>HER2</em>-negative women. The pooled estimates of the benefits associated with anthracyclines in all patients included in this meta-analysis
                     are consistent with those reported by the EBCTCG systematic overview (<a id="xref-ref-1-2" class="xref-bibr" href="#ref-1">1</a>) both in terms of disease-free survival (HR of relapse = 0.90 in our analysis vs 0.89 in the EBCTCG overview) and overall
                     survival (HR of death from any cause = 0.91 vs 0.84, respectively). Our results confirm that the added benefit of adjuvant
                     chemotherapy with anthracyclines is confined to women who have breast tumors in which <em>HER2</em> is overexpressed or amplified. Most of the studies included in this analysis showed this association (<a id="xref-ref-8-13" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-9-6" class="xref-bibr" href="#ref-9">9</a>,<a id="xref-ref-11-6" class="xref-bibr" href="#ref-11">11</a>–<a id="xref-ref-14-6" class="xref-bibr" href="#ref-14">14</a>), and two studies (<a id="xref-ref-10-6" class="xref-bibr" href="#ref-10">10</a>,<a id="xref-ref-15-11" class="xref-bibr" href="#ref-15">15</a>) reported a statistically significant interaction between <em>HER2</em> status and adjuvant anthracyclines for disease-free survival. The statistically significant interaction for both disease-free
                     and overall survival revealed by our meta-analysis provides convincing statistical evidence of a quantitative interaction
                     between <em>HER2</em> status and responsiveness to adjuvant anthracyclines.
                  </p>
                  <p id="p-37">Our study has several limitations that should be considered when interpreting the data. First, as with all meta-analyses,
                     our findings and interpretations are limited by the quality and quantity of available evidence (ie, trials) on the effects
                     of adjuvant anthracyclines according to <em>HER2</em> status. Second, we used published summary results rather than individual patient data, and it was not possible to check the
                     original data and analyses, to undertake additional evaluations, or to perform a centralized reassessment of participants'
                     <em>HER2</em> status. Third, a number of unpublished studies might exist, which could lead to possible publication bias if studies that
                     did not show an interaction between <em>HER2</em> status and treatment with anthracyclines were less likely to be published. However, we found no indication of publication
                     bias by using statistical methods that are designed to detect it. A fourth limitation of our meta-analysis is the variability
                     in methods used to assess <em>HER2</em> status. However, a sensitivity analysis for methods of <em>HER2</em> assessment (immunohistochemistry vs fluorescence in situ hybridization) showed no substantial differences in the degree of
                     interaction between <em>HER2</em> status and the efficacy of adjuvant anthracyclines according to type of <em>HER2</em> assay.
                  </p>
                  <p id="p-38">Further support for our results comes from studies that have compared different dose intensities of adjuvant anthracyclines
                     (<a id="xref-ref-8-14" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>,<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>). These studies have shown that the benefit of more intensive anthracycline-based regimens is limited to <em>HER2</em>-positive patients.
                  </p>
                  <p id="p-39">Interpretation of our results must also take into account that <em>HER2</em> is not the true anthracycline molecular target and that changes in expression of the topoisomerase II alpha gene or protein
                     may be a more accurate and biologically related predictive factor of response to anthracyclines. Indeed, several studies have
                     suggested that the added benefit of adjuvant anthracyclines may be restricted to the small proportion of patients whose tumors
                     have amplification of or deletions in the topoisomerase II alpha gene itself or in topoisomerase II alpha protein expression
                     (<a id="xref-ref-8-15" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-9-7" class="xref-bibr" href="#ref-9">9</a>,<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>). Furthermore, topoisomerase II alpha protein levels are regulated by gene amplification and by the tumor proliferation rate
                     (<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>), which suggests that anthracycline superiority may also be seen in the subset of <em>HER2</em>-negative tumors that overexpress topoisomerase II alpha protein. Clarification of whether topoisomerase II alpha status rather
                     than <em>HER2</em> status is actually predictive of increased sensitivity to anthracyclines will require a meta-analysis of individual patient
                     data from randomized clinical trials that have compared adjuvant anthracyclines with non–anthracycline-based regimens and
                     that include patients for whom both the <em>HER2</em> status and the topoisomerase II alpha status are known.
                  </p>
                  <p id="p-40">In conclusion, our results suggest that <em>HER2</em> status is a predictor of responsiveness to adjuvant anthracycline therapy for early breast cancer. The absence, in our study,
                     of any effect of anthracyclines observed in patients with <em>HER2</em>-negative disease suggests that this group of patients could be spared unnecessary toxic effects related to the use of this
                     class of agents and raises questions as to the appropriateness of control arms in randomized clinical trials in which anthracycline-based
                     regimens are used in unselected patient populations.
                  </p>
               </div>
               <div class="section" id="sec-20">
                  <div class="section-nav"><a href="#sec-19" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Funding</h2>
                  <p id="p-41">Italian Association for Cancer Research; University of Genoa, Italy.</p>
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-20" title="Funding" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-7">
                        <p id="p-42">The sponsors had no role in the study design, data collection and analysis, interpretation of the results, the preparation
                           of the manuscript, or the decision to submit the manuscript for publication.
                        </p>
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© The Author 2007. Published by Oxford University Press.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">1.</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text"
                           id="ref-1">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.1"
                             data-doi="10.1016/S0140-6736(05)66544-0">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Early Breast Cancer Trialists' Collaborative Group (EBCTCG)</span>. <span class="cit-article-title">Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the
                                    randomised trials</span>. <abbr class="cit-jnl-abbrev">Lancet.</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">365</span>:<span class="cit-fpage">1687</span>-<span class="cit-lpage">1717</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(05)66544-0&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15894097&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000229082300022&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">2.</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2. in text"
                           id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.2">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fisher</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Brown</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dimitrov</span>  <span class="cit-name-given-names">NV</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,
                                    methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen non responsive tumours: results from
                                    the National Surgical Adjuvant Breast and Bowel Project B-15</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">8</span>:<span class="cit-fpage">1483</span>-<span class="cit-lpage">1496</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=8/9/1483"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">3.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.1.14.3">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fisher</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Anderson</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tan-Chiu</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical
                                    Adjuvant Breast and Bowel Project B-23</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>:<span class="cit-fpage">931</span>-<span class="cit-lpage">942</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/4/931"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">4.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.1.14.4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Piccart</span>  <span class="cit-name-given-names">MJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Di Leo</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Beauduin</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate,
                                    and fluorouracil in node-positive breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>:<span class="cit-fpage">3103</span>-<span class="cit-lpage">3110</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/12/3103"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">5.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.1.14.5"
                             data-doi="10.1002/1097-0142(20001215)89:12&lt;2521::AID-CNCR2&gt;3.0.CO;2-F">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bang</span>  <span class="cit-name-given-names">SM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Heo</span>  <span class="cit-name-given-names">DS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lee</span>  <span class="cit-name-given-names">KH</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal
                                    women with axillary lymph node positive breast carcinoma</span>. <abbr class="cit-jnl-abbrev">Cancer.</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">89</span>:<span class="cit-fpage">2521</span>-<span class="cit-lpage">2526</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(20001215)89:12%3C2521::AID-CNCR2%3E3.0.CO;2-F&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11135211&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adjuvant%20doxorubicin%20and%20cyclophosphamide%20versus%20cyclophosphamide%2C%20methotrexate%2C%20and%205-fluorouracil%20chemotherapy%20in%20premenopausal%20women%20with%20axillary%20lymph%20node%20positive%20breast%20carcinoma&amp;author=SM%20Bang&amp;author=DS%20Heo&amp;author=KH%20Lee&amp;publication_year=2000&amp;journal=Cancer.&amp;volume=89&amp;pages=2521-2526">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">6.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.1.14.6"
                             data-doi="10.1016/S0959-8049(02)00452-5">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Colozza</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bisagni</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mosconi</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer.</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">38</span>:<span class="cit-fpage">2279</span>-<span class="cit-lpage">2288</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0959-8049(02)00452-5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12441265&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000179783700019&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Epirubicin%20versus%20CMF%20as%20adjuvant%20therapy%20for%20stage%20I%20and%20II%20breast%20cancer%3A%20a%20prospective%20randomised%20study&amp;author=M%20Colozza&amp;author=G%20Bisagni&amp;author=AM%20Mosconi&amp;publication_year=2002&amp;journal=Eur%20J%20Cancer.&amp;volume=38&amp;pages=2279-2288">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">7.</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text"
                           id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.7">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moliterni</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bonadonna</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Valagussa</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ferrari</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zambetti</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Cyclophosphamide, methotrexate and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast
                                    cancer with one to three positive axillary nodes</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol.</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">9</span>:<span class="cit-fpage">1124</span>-<span class="cit-lpage">1130</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=9/7/1124"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">8.</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text"
                           id="ref-8">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.8">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Di Leo</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gancberg</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Larsimont</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients
                                    randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res.</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">8</span>:<span class="cit-fpage">1107</span>-<span class="cit-lpage">1116</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=8/5/1107"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">9.</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text"
                           id="ref-9">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.9"
                             data-doi="10.1200/JCO.2005.11.007">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Knoop</span>  <span class="cit-name-given-names">AS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Knudsen</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Balslev</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients
                                    randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>:<span class="cit-fpage">7483</span>-<span class="cit-lpage">7490</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/30/7483"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">10.</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text"
                           id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.10"
                             data-doi="10.1093/jnci/90.18.1361">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Paik</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bryant</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Park</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst</abbr> <span class="cit-pub-date">1998</span>;<span class="cit-vol">90</span>:<span class="cit-fpage">1361</span>-<span class="cit-lpage">1370</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=90/18/1361"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">11.</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text"
                           id="ref-11">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.11"
                             data-doi="10.1093/jnci/92.24.1991">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Paik</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bryant</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tan-Chiu</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol
                                    B-15</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst.</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">92</span>:<span class="cit-fpage">1991</span>-<span class="cit-lpage">1998</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=92/24/1991"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">12.</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text"
                           id="ref-12">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.12">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">De Laurentiis</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Caputo</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Massarelli</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Forestieri</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vernaglia</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Carlomagno</span>  <span class="cit-name-given-names">C</span></span></li>
                              </ol><cite>. <span class="cit-article-title">HER2 expression and anthracycline effect: results from the Naple GUN 3 randomized trial</span>. <abbr class="cit-jnl-abbrev">Proc Am Soc Clin Oncol.</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">20</span>:<span class="cit-fpage">A133</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=HER2%20expression%20and%20anthracycline%20effect%3A%20results%20from%20the%20Naple%20GUN%203%20randomized%20trial&amp;author=M%20De%20Laurentiis&amp;author=F%20Caputo&amp;author=E%20Massarelli&amp;author=V%20Forestieri&amp;author=A%20Vernaglia&amp;author=C%20Carlomagno&amp;publication_year=2001&amp;journal=Proc%20Am%20Soc%20Clin%20Oncol.&amp;volume=20&amp;pages=A133">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">13.</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text"
                           id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.13"
                             data-doi="10.1200/JCO.2003.04.021">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moliterni</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Menard</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Valagussa</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">21</span>:<span class="cit-fpage">458</span>-<span class="cit-lpage">462</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=21/3/458"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">14.</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text"
                           id="ref-14">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.14">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Colozza</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sidoni</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mosconi</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil
                                    with epirubicin in patients with stage I/II breast cancer: long-term results</span>. <abbr class="cit-jnl-abbrev">Clin Breast Cancer</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">6</span>:<span class="cit-fpage">253</span>-<span class="cit-lpage">259</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=16137437&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=HER2%20overexpression%20as%20a%20predictive%20marker%20in%20a%20randomized%20trial%20comparing%20adjuvant%20cyclophosphamide%2Fmethotrexate%2F5-fluorouracil%20with%20epirubicin%20in%20patients%20with%20stage%20I%2FII%20breast%20cancer%3A%20long-term%20results&amp;author=M%20Colozza&amp;author=A%20Sidoni&amp;author=AM%20Mosconi&amp;publication_year=2005&amp;journal=Clin%20Breast%20Cancer&amp;volume=6&amp;pages=253-259">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">15.</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text"
                           id="ref-15">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.15"
                             data-doi="10.1056/NEJMoa054504">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pritchard</span>  <span class="cit-name-given-names">KI</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shepherd</span>  <span class="cit-name-given-names">LE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">O'Malley</span>  <span class="cit-name-given-names">FP</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">HER2 and responsiveness of breast cancer to adjuvant chemotherapy</span>. <abbr class="cit-jnl-abbrev">N Engl J Med.</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">354</span>:<span class="cit-fpage">2103</span>-<span class="cit-lpage">2111</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa054504&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16707747&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000237575400004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=HER2%20and%20responsiveness%20of%20breast%20cancer%20to%20adjuvant%20chemotherapy&amp;author=KI%20Pritchard&amp;author=LE%20Shepherd&amp;author=FP%20O%27Malley&amp;publication_year=2006&amp;journal=N%20Engl%20J%20Med.&amp;volume=354&amp;pages=2103-2111">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">16.</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16. in text"
                           id="ref-16">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.16"
                             data-doi="10.1016/S0002-9440(10)64952-8">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jarvinen</span>  <span class="cit-name-given-names">TAH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tanner</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rantanen</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase
                                    II inhibitor doxorubicin in breast cancer</span>. <abbr class="cit-jnl-abbrev">Am J Pathol.</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">156</span>:<span class="cit-fpage">839</span>-<span class="cit-lpage">847</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0002-9440(10)64952-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10702400&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000085702600014&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Amplification%20and%20deletion%20of%20topoisomerase%20IIa%20associate%20with%20ErbB-2%20amplification%20and%20affect%20sensitivity%20to%20topoisomerase%20II%20inhibitor%20doxorubicin%20in%20breast%20cancer&amp;author=TAH%20Jarvinen&amp;author=M%20Tanner&amp;author=V%20Rantanen&amp;publication_year=2000&amp;journal=Am%20J%20Pathol.&amp;volume=156&amp;pages=839-847">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">17.</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text"
                           id="ref-17">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.17"
                             data-doi="10.7326/0003-4819-116-1-78">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Oxman</span>  <span class="cit-name-given-names">AD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Guyatt</span>  <span class="cit-name-given-names">GH</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A consumers' guide to subgroup analyses</span>. <abbr class="cit-jnl-abbrev">Ann Intern Med.</abbr> <span class="cit-pub-date">1992</span>;<span class="cit-vol">116</span>:<span class="cit-fpage">78</span>-<span class="cit-lpage">84</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.7326/0003-4819-116-1-78&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=1530753&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1992GX15700012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20consumers%27%20guide%20to%20subgroup%20analyses&amp;author=AD%20Oxman&amp;author=GH%20Guyatt&amp;publication_year=1992&amp;journal=Ann%20Intern%20Med.&amp;volume=116&amp;pages=78-84">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">18.</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text"
                           id="ref-18">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.18" data-doi="10.2307/2533446">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Begg</span>  <span class="cit-name-given-names">CB</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mazumdar</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Operating characteristics of a rank correlation test for publication bias</span>. <abbr class="cit-jnl-abbrev">Biometrics</abbr> <span class="cit-pub-date">1994</span>;<span class="cit-vol">50</span>:<span class="cit-fpage">1088</span>-<span class="cit-lpage">1101</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2307/2533446&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7786990&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1994QP05000016&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Operating%20characteristics%20of%20a%20rank%20correlation%20test%20for%20publication%20bias&amp;author=CB%20Begg&amp;author=M%20Mazumdar&amp;publication_year=1994&amp;journal=Biometrics&amp;volume=50&amp;pages=1088-1101">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">19.</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19. in text"
                           id="ref-19">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.19"
                             data-doi="10.1136/bmj.315.7109.629">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Egger</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smith</span>  <span class="cit-name-given-names">GD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schneider</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Bias in meta-analysis detected by a simple, graphical test</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr> <span class="cit-pub-date">1997</span>;<span class="cit-vol">315</span>:<span class="cit-fpage">629</span>-<span class="cit-lpage">634</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=315/7109/629"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">20.</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20. in text"
                           id="ref-20">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.20">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vera</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Albanell</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lirola</span>  <span class="cit-name-given-names">JL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bermejo</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sole</span>  <span class="cit-name-given-names">LA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baselga</span>  <span class="cit-name-given-names">J</span></span></li>
                              </ol><cite>. <span class="cit-article-title">HER2 overexpression as a predictor of survival in a trial comparing adjuvant FAC and CMF in breast cancer</span>. <abbr class="cit-jnl-abbrev">Proc Am Soc Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">18</span>:<span class="cit-fpage">A265</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=HER2%20overexpression%20as%20a%20predictor%20of%20survival%20in%20a%20trial%20comparing%20adjuvant%20FAC%20and%20CMF%20in%20breast%20cancer&amp;author=R%20Vera&amp;author=J%20Albanell&amp;author=JL%20Lirola&amp;author=B%20Bermejo&amp;author=LA%20Sole&amp;author=J%20Baselga&amp;publication_year=1999&amp;journal=Proc%20Am%20Soc%20Clin%20Oncol&amp;volume=18&amp;pages=A265">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">21.</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21. in text"
                           id="ref-21">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.21"
                             data-doi="10.1038/sj.bjc.6602660">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Del Mastro</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bruzzi</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nicolo</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients</span>. <abbr class="cit-jnl-abbrev">Br J Cancer.</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">93</span>:<span class="cit-fpage">7</span>-<span class="cit-lpage">14</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6602660&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15970926&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000230265000002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=HER2%20expression%20and%20efficacy%20of%20dose-dense%20anthracycline-containing%20adjuvant%20chemotherapy%20in%20breast%20cancer%20patients&amp;author=L%20Del%20Mastro&amp;author=P%20Bruzzi&amp;author=G%20Nicolo&amp;publication_year=2005&amp;journal=Br%20J%20Cancer.&amp;volume=93&amp;pages=7-14">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">22.</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22. in text"
                           id="ref-22">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.22"
                             data-doi="10.1056/NEJM199405053301802">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Muss</span>  <span class="cit-name-given-names">HB</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thor</span>  <span class="cit-name-given-names">AD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Berry</span>  <span class="cit-name-given-names">DA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med.</abbr> <span class="cit-pub-date">1994</span>;<span class="cit-vol">330</span>:<span class="cit-fpage">1260</span>-<span class="cit-lpage">1266</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM199405053301802&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7908410&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1994NJ51200002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=C-erbB-2%20expression%20and%20response%20to%20adjuvant%20therapy%20in%20women%20with%20node-positive%20early%20breast%20cancer&amp;author=HB%20Muss&amp;author=AD%20Thor&amp;author=DA%20Berry&amp;publication_year=1994&amp;journal=N%20Engl%20J%20Med.&amp;volume=330&amp;pages=1260-1266">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">23.</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23. in text"
                           id="ref-23">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.23">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Di Leo</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Claudino</span>  <span class="cit-name-given-names">WM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pestrin</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Licitra</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Biganzoli</span>  <span class="cit-name-given-names">L</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Using specific cytotoxics with a targeted mind</span>. <abbr class="cit-jnl-abbrev">Breast.</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">16</span>:<span class="cit-fpage">S120</span>-<span class="cit-lpage">S126</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=17720501&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Using%20specific%20cytotoxics%20with%20a%20targeted%20mind&amp;author=A%20Di%20Leo&amp;author=WM%20Claudino&amp;author=M%20Pestrin&amp;author=S%20Licitra&amp;author=L%20Biganzoli&amp;publication_year=2007&amp;journal=Breast.&amp;volume=16&amp;pages=S120-S126">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">24.</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24. in text"
                           id="ref-24">↵</a><div class="cit ref-cit ref-journal" id="cit-100.1.14.24">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jarvinen</span>  <span class="cit-name-given-names">TA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kononen</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pelto-Huikko</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Isola</span>  <span class="cit-name-given-names">J</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Expression of topoisomerase IIa is associated with rapid cell proliferation, aneuploidy, and c-erb B-2 overexpression in breast
                                    cancer</span>. <abbr class="cit-jnl-abbrev">Am J Pathol.</abbr> <span class="cit-pub-date">1996</span>;<span class="cit-vol">148</span>:<span class="cit-fpage">2073</span>-<span class="cit-lpage">2082</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8669491&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996UN46800035&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Expression%20of%20topoisomerase%20IIa%20is%20associated%20with%20rapid%20cell%20proliferation%2C%20aneuploidy%2C%20and%20c-erb%20B-2%20overexpression%20in%20breast%20cancer&amp;author=TA%20Jarvinen&amp;author=J%20Kononen&amp;author=M%20Pelto-Huikko&amp;author=J%20Isola&amp;publication_year=1996&amp;journal=Am%20J%20Pathol.&amp;volume=148&amp;pages=2073-2082">Google Scholar</a></div>
                        </div>
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">IN THIS ISSUE<span class="cit-sep cit-sep-after-article-section">:</span> </span><span class="cit-title">IN THIS ISSUE </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2008<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">100 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>1<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djm296 </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>January 1, 2008 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;100/1/1 pdf_extract,full,reprint"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/100/1/1.1.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/100/1/1.1.full" rel="full-text">Full Text (HTML)</a></li>
                           <li><a href="/content/100/1/1.1.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                           <li class="last-item"><a href="/content/100/1/1.1/suppl/DC1" rel="supplemental-data"
                                 class="dslink-japanese-translation-data-supplement">Japanese Translation, Data Supplement</a></li>
                        </ul>  
                     </div> 
                  </div>
                  <div class="cit has-earlier-version">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">MEMO TO THE MEDIA<span class="cit-sep cit-sep-after-article-section">:</span> </span><ul class="cit-auth-list">
                           <li class="first-item"><span class="cit-auth cit-auth-type-author">Liz Savage</span><span class="cit-sep cit-sep-two-item-separator"> and</span></li>
                           <li class="last-item"><span class="cit-auth cit-auth-type-author">Andrea Widener</span></li>  
                        </ul><span class="cit-title">Anthracyclines Improve Survival in HER2-Positive Breast Cancer Patients </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2008<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">100 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>1<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djm321 </span><span class="cit-ahead-of-print-date"><span class="cit-sep cit-sep-before-article-ahead-of-print-date">first published online </span>December 25, 2007 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;100/1/1-a pdf_extract,full,reprint"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/100/1/1.2.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/100/1/1.2.full" rel="full-text">Full Text (HTML)</a></li>
                           <li class="last-item"><a href="/content/100/1/1.2.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/100/1/13.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/100/1/21.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/100/1.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2008) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    100
                                    </span><span class="slug-issue">
                                    (1):
                                    </span><span class="slug-pages">
                                    14-20.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djm252" class="slug-doi">10.1093/jnci/djm252</span>
                                    </span>
                                 </cite>
                              
                              
                              <span class="slug-metadata-note ahead-of-print">
                                 
                                 First published online
                                 
                                 <span class="slug-ahead-of-print-date">December 25, 2007</span>
                                 </span>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/100/1/14.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/100/1/14.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/100/1/14/suppl/DC1" rel="supplemental-data"
                              class="dslink-jnci-podcast">JNCI Podcast</a></li>
                        <li class="cb-versions">
                           <div><span id="pap-all-versions-label">All Versions of this Article:</span><ol class="version-list">
                                 <li><a href="/content/early/2007/12/25/jnci.djm252">djm252v1</a></li>
                                 <li class="current-li"><span>100/1/14</span> <span class="current-version">most recent</span></li>
                              </ol>
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=ARTICLES&amp;sortspec=date&amp;submit=Submit">Article</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;100/1/14" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B100%2F1%2F14&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/100/1/14.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=100/1/14&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/100/1/14.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3Bdjm252&amp;citation=Gennari%20et%20al.%20100%20%281%29:%2014&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B100%2F1%2F14&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=18159072&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B100%2F1%2F14">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B100%2F1%2F14">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=HER2%20Status%20and%20Efficacy%20of%20Adjuvant%20Anthracyclines%20in%20Early%20Breast%20Cancer%3A%20A%20Pooled%20Analysis%20of%20Randomized%20Trials%3A%20&amp;publicationDate=01%2F02%2F2008&amp;author=Alessandra%20Gennari%2C%20Maria%20Pia%20Sormani%2C%20Paolo%20Pronzato%2C%20Matteo%20Puntoni%2C%20Mariantonietta%20Colozza%2C%20Ulrich%20Pfeffer%2C%20Paolo%20Bruzzi&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjm252&amp;volumeNum=100&amp;issueNum=1&amp;startPage=14&amp;endPage=20&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/100/1/14.full?cited-by=yes&amp;legid=jnci;100/1/14#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/100/1/14" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/100/1/14?access_num=/jnci/100/1/14" rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F100%2F1%2F14&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/100/1/14.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AGennari%20author%3AA.%22"
                              class="cb-art-gs-auth author-link">Articles by  Gennari, A.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3ABruzzi%20author%3AP.%22"
                              class="cb-art-gs-auth author-link">Articles by  Bruzzi, P.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/100/1/14.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=18159072&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Gennari%20A&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Gennari, A.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Sormani%20MP&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Sormani, M. P.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Pronzato%20P&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Pronzato, P.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Puntoni%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Puntoni, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Colozza%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Colozza, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Pfeffer%20U&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Pfeffer, U.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Bruzzi%20P&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Bruzzi, P.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/100/1/14.full?related-urls=yes&amp;legid=jnci;100/1/14#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B100%2F1%2F14&amp;current-view-path=/content/100/1/14.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/1/14&amp;title=HER2%20Status%20and%20Efficacy%20of%20Adjuvant%20Anthracyclines%20in%20Early%20Breast%20Cancer%3A%20A%20Pooled%20Analysis%20of%20Randomized%20Trials+--+Gennari%20et%20al.%20100%20%281%29%3A%2014+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djm252&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/1/14&amp;title=HER2%20Status%20and%20Efficacy%20of%20Adjuvant%20Anthracyclines%20in%20Early%20Breast%20Cancer%3A%20A%20Pooled%20Analysis%20of%20Randomized%20Trials+--+Gennari%20et%20al.%20100%20%281%29%3A%2014+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djm252&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/100/1/14&amp;title=HER2%20Status%20and%20Efficacy%20of%20Adjuvant%20Anthracyclines%20in%20Early%20Breast%20Cancer%3A%20A%20Pooled%20Analysis%20of%20Randomized%20Trials+--+Gennari%20et%20al.%20100%20%281%29%3A%2014+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djm252&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/1/14&amp;title=HER2%20Status%20and%20Efficacy%20of%20Adjuvant%20Anthracyclines%20in%20Early%20Breast%20Cancer%3A%20A%20Pooled%20Analysis%20of%20Randomized%20Trials+--+Gennari%20et%20al.%20100%20%281%29%3A%2014+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djm252&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/1/14&amp;title=HER2%20Status%20and%20Efficacy%20of%20Adjuvant%20Anthracyclines%20in%20Early%20Breast%20Cancer%3A%20A%20Pooled%20Analysis%20of%20Randomized%20Trials+--+Gennari%20et%20al.%20100%20%281%29%3A%2014+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djm252&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/1/14&amp;title=HER2%20Status%20and%20Efficacy%20of%20Adjuvant%20Anthracyclines%20in%20Early%20Breast%20Cancer%3A%20A%20Pooled%20Analysis%20of%20Randomized%20Trials+--+Gennari%20et%20al.%20100%20%281%29%3A%2014+--+Journal%20of%20the%20National%20Cancer%20Institute&amp;doi=10.1093/jnci/djm252&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-11">Methods</a></li>
                        <li><a href="#sec-15">Results</a></li>
                        <li><a href="#sec-19">Discussion</a></li>
                        <li><a href="#sec-20">Funding</a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/100/1/14.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/100/1/14.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>